CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 250 enrolled
Drug / intervention
Faecal Calprotectin Home Test +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04340895
NCT04340895N/ACompleted

Pragmatic Randomized Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis

Ferring Pharmaceuticals·interventional·Posted Apr 10, 2020·Updated Sep 19, 2024

In Brief

A clinical study evaluating Faecal Calprotectin Home Test and PRO-2 Scoring for Mild-to-moderate Ulcerative Colitis. Completed, enrolled 250 participants across 42 sites in 6 countries.

Detailed Summary

The purpose of this study is to provide evidence that a therapy of Ulcerative Colitis (UC) disease adjusted on tight monitoring of non-invasive parameters, such as clinical symptoms and faecal calprotectin (FC) (substance that is released when intestines are inflamed and that can be measured in faeces), can provide significantly higher benefit for the participants in terms of disease control and quality of life (QoL) improvement, compared to a symptom-based approach only.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCzechia, Hungary, Italy, Netherlands, Poland, Slovakia
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedApr 10, 2020
Enrollment StartOct 14, 2019
Primary CompletionOct 20, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.2 years ago

Interventions

Faecal Calprotectin Home Testother

A non-invasive, in vitro diagnostic test for the determination of FC levels in human stool samples in combination with the dedicated 'CalproSmart' smartphone application. This test helps participants to self-monitor their FC levels at their own homes, ensuring an adequate and effective medical treatment regimen performed by the investigator.

PRO-2 Scoringother

Monitoring of clinical symptoms will be performed by PRO-2 scoring, which includes rectal bleeding (RB) and stool frequency (SF) assessment obtained within the last 3-days.